HIGHLIGHTS
- who: Gastrointestinal stromal tumors- ICAM- et al. from the (UNIVERSITY) have published the research work: Serum level of ICAM-4 and Markers among Patients Process: Submission:08/24/2022 Acceptance:01/11/2023 Immunological Study of ICAM-4 and Markers among Patients in Babylon, in the Journal: (JOURNAL)
- what: This study was conducted to investigate the roles of ICAM-4 and markers among benign and malignant (GISTs). In the current study, the basic characteristics of the variables were compared between patients with GIT tumors and healthy controls. This study discovered higher serum IFN-u03b3 levels . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.